Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002450
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.
- Detailed Description
Patients are randomized 2:1 to add tenofovir DF once daily or placebo to their existing antiretroviral regimen in a blinded manner. Patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs taken prior to study entry. Patients and physicians are strongly discouraged from making changes in their antiviral therapies for at least 24 weeks post-randomization. After Week 24, changes in background antiretroviral therapy are permitted. At 24 weeks post-randomization, patients randomized to receive placebo are crossed over to receive open-label tenofovir DF once daily for the remainder of the 48-week study. While on study drug, patients are monitored for safety using periodic physical examinations and serial laboratory tests. Additionally, changes in plasma HIV RNA levels and CD4 cell counts are monitored to assess antiviral efficacy. At the end of the 48-week study period, patients are rolled over into extended dosing until tenofovir DF is commercially available or Gilead Sciences terminates the study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (61)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
Ocean View Internal Medicine
🇺🇸Long Beach, California, United States
St Mary's Med Ctr
🇺🇸Long Beach, California, United States
AIDS Healthcare Foundation-Research Center
🇺🇸Los Angeles, California, United States
Kaiser Permanente LAMC
🇺🇸Los Angeles, California, United States
LAC / USC Med Ctr / Infectious Diseases
🇺🇸Los Angeles, California, United States
Cedars Sinai Med Ctr
🇺🇸Los Angeles, California, United States
Tower Infectious Diseases / Med Associates Inc
🇺🇸Los Angeles, California, United States
Robert Scott MD
🇺🇸Oakland, California, United States
Scroll for more (51 remaining)Univ of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States